title: Levosimendan improves pro/anti-inflammatory cytokines imbalance in male patients with advanced heart failure. A randomized, double-blind, placebo-controlled study.
authors.forename: Anna Laura
authors.initials: AL
authors.lastname: Pasqui
authors.forename: Silvia
authors.initials: S
authors.lastname: Maffei
authors.forename: Michela
authors.initials: M
authors.lastname: Di Renzo
authors.forename: Gerarda
authors.initials: G
authors.lastname: Pompella
authors.forename: Alberto
authors.initials: A
authors.lastname: Auteri
authors.forename: Luca
authors.initials: L
authors.lastname: Puccetti
mesh_terms: D016207:Cytokines / Q000097:blood*; D004311:Double-Blind Method; D006333:Heart Failure / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D011724:Pyridazines / Q000627:therapeutic use*; D000077464:Simendan; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D016207:Cytokines; D006835:Hydrazones; D010919:Placebos; D011724:Pyridazines; D014665:Vasodilator Agents; D000077464:Simendan